CTOs on the Move

Fairview-University Medical Center

www.fairview-university.fairview.org

 
Fairview-University Medical Center is a Minneapolis, MN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details

Similar Companies

Virginia Physicians

Virginia Physicians is a Glen Allen, VA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Provation Medical

Provation is a leading provider of clinical productivity software for healthcare professionals, with solutions for intelligent procedure documentation (Provation® MD and Provation® Apex), order set and care plan management (Provation® Order Sets and Provation® Care Plans), and EHR-embedded clinical documentation templates (Provation® Clinic Note). Our software helps providers increase operational efficiencies, business profitability and regulatory compliance by improving quality, streamlining workflows and enabling the generation of insights. Trusted by leading physicians globally, we serve approximately 1,500 hospitals and 1,000 ambulatory surgery centers (ASCs), including 16 of the top 20 U.S. hospitals for gastroenterology (GI) and GI surgery. Provation is headquartered in Minneapolis, MN and is owned by Clearlake Capital Group, L.P.

Zetta Medical Technologies

Zetta Medical Technologies is one of the leading providers in Healthcare, Pharmaceuticals, and Biotech. It is based in Lake Zurich, IL. To find more information about Zetta Medical Technologies, please visit www.zettamed.com

Simply Prescriptions

Simply Prescriptions is a Utica, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Clarvista Medical

ClarVista Medical` based in Aliso Viejo` California is a leading developer of innovative products to treat challenging ophthalmic conditions. In 2012 and in conjunction with series A financing` ClarVista was spun out from Prospex Medical` a medical device incubator` to pursue the development of the HARMONI™ IOL. Between 2012 and 2014` the company developed the first generation HARMONI™ system` conducted thorough first-in-human clinical study and developed a broad portfolio of intellectual property. In 2015 the company closed on a series B financing of $14M which will be used to develop the second generation HAROMONI™ system` conduct a larger feasibility clinical trial and obtain key regulatory approvals including CE mark and US IDE.